STENOCARE / Investor relations / News archiveNews archive 15-01-2025STENOCARE – The new innovative ASTRUM 10-10 product is now available for German patients 15-01-2025STENOCARE - Deadline Soon for Subscription to New Shares at DKK 0.50 Each 10-01-2025STENOCARE A/S announces guarantee commitments in ongoing rights issue 09-01-2025STENOCARE – Deadline soon to subscribe for new shares at DKK 0.50 each 07-01-2025STENOCARE A/S: The subscription period in Stenocare’s conditional rights issue begins today for the time limited offer of DKK 0,50 per new share 03-01-2025STENOCARE’s Innovative ASTRUM 10-10 Product Now Available for Norwegian Patients 18-12-2024STENOCARE A/S: Conditional Rights Issue of up to 20.2 mDKK 18-12-2024Communiqué from extraordinary general meeting in STENOCARE 17-12-2024STENOCARE Gains Danish Approval for New Medical Cannabis CBD100 oil 10-12-2024STENOCARE 3.0 Strategy: Management Shares Insights in Exclusive Interview with Proinvestor.com 02-12-2024STENOCARE – Innovative New ASTRUM Product Officially Approved for Sale in Norway 28-11-2024STENOCARE Celebrates Denmark’s Permanent Legalisation of Medical Cannabis 26-11-2024STENOCARE 3.0: Shifting Strategy to Focus on Trading and exit from Production 26-11-2024Notice to Extraordinary General Meeting in STENOCARE A/S 19-11-2024STENOCARE Welcomes Danish Health Minister’s Decision to Permanently Legalise Medical Cannabis for Patients 01-11-2024STENOCARE Change in the Board of Directors 14-10-2024STENOCARE updates guidance for 2024 20-08-2024STENOCARE updates guidance for 2024 31-07-2024New innovative Stenocare Astrum 10-10 oil product is ready for sale in Germany 28-06-2024STENOCARE A/S: Directed issue, refinancing of debt from a major shareholder and new dates 25-06-2024TO2 Warrant Exercise subscribed to 88.3% 20-06-2024STENOCARE: Notice for deadline of subscribing at the discounted price of DKK 3.16 per share 18-06-2024STENOCARE A/S: Notice for deadline of trading TO2 Warrants 17-06-2024STENOCARE is expanding into Canada 13-06-2024STENOCARE A/S: Publication of investment brochure 12-06-2024STENOCARE is shortlisted for European Cannabis Company of the Year 07-06-2024STENOCARE A/S: Announcement of Exercise Price of Warrants of Series TO2 31-05-2024An Update on STENOCARE's Strong Product Pipeline 23-05-2024STENOCARE launch next generation medical cannabis oil product in Australia – six months ahead of schedule 22-05-2024STENOCARE is sharing early information about the upcoming share issue “TO2 Warrant” transaction in June 2024 14-05-2024COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE 22-04-2024Notice to Annual General Meeting in STENOCARE A/S 18-04-2024From today, the new STENOCARE THC/CBD medical cannabis oil product is available for sale in Denmark 12-03-2024New Stenocare product ready for sale in Australia 26-02-2024Major milestone reached: STENOCARE receives approval to sell a new medical cannabis oil product in Denmark 05-02-2024Communiqué from extraordinary general meeting in STENOCARE 12-01-2024STENOCARE financing need has been completed as planned incl solution for refinancing of debt 12-01-2024Notice to Extraordinary General Meeting in STENOCARE A/S 29-12-2023STENOCARE: How to receive TO1 Warrant Compensation 21-12-2023STENOCARE A/S: Consolidation of founder’s shareholdings 21-12-2023TO1 Warrant Exercise subscribed to 76.7% 19-12-2023Founders of Stenocare join directed issue 19-12-2023Shareholder invests 4.7 mDKK in STENOCARE A/S 17-12-2023STENOCARE: The deadline for using TO1 Warrants is Dec 19 14-12-2023STENOCARE expands in Australia 13-12-2023STENOCARE: The deadline for trading TO1 Warrants is Dec 15 11-12-2023STENOCARE Executive team to exercise TO1 Warrants 06-12-2023STENOCARE A/S: Announcement of Exercise Price of Warrants of Series TO1 04-12-2023STENOCARE confirms guidance and reports limited capital requirements ahead of the first TO1-warrant subscription starting on 6 December 2023 29-11-2023Amended terms relating to upcoming TO1 and TO2 warrants 23-11-2023Australia due to become a major market for STENOCARE in 2024 06-11-2023Updated guidance: Record sales in 2023 and break-even in 2024 06-11-2023STENOCARE: One-off return of products from Norway 30-10-2023STENOCARE ready to ship medical cannabis to German patients 27-09-2023Significant growth in market share and patients in Denmark 18-09-2023STENOCARE market update – September 2023 01-09-2023STENOCARE’s commitment to supply medical cannabis to patients 27-07-2023STENOCARE update on their strong Danish product pipeline 26-06-2023STENOCARE A/S: Conversion of 5.0 mDKK of debt 13-06-2023Communiqué from extraordinary general meeting in STENOCARE 12-06-2023STENOCARE Units Rights Issue subscribed to 127% 06-06-2023High profiled medical doctor and entrepreneur joins STENOCARE’s ongoing share-issue 02-06-2023STENOCARE reports on significant progress in development of its new innovative medical cannabis product 30-05-2023STENOCARE launches groundbreaking IT-platform for Online Clinics 25-05-2023STENOCARE PRODUCT APPROVED AND READY FOR SALE IN GERMANY 24-05-2023STENOCARE Unit Right Issue - First day of subscription 15-05-2023Notice to Extraordinary General Meeting in STENOCARE A/S 15-05-2023STENOCARE A/S: Unit Rights Issue of up to 29.7 mDKK 11-04-2023COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE 20-03-2023Notice to Annual General Meeting in STENOCARE A/S 09-01-2023STENOCARE A/S (“Stenocare”) delivered products to its 5 markets during Q4 2022 corresponding to net sales of 2.8 mDKK and is on track for its sales expectations for 2023 in the range of 15-20 mDKK 03-01-2023Investor Update: The first shipment of Stenocare medical cannabis oil products has arrived in Norway and the products are ready for patients. 02-01-2023Investor Update: Today, the new STENOCARE CBD medical cannabis oil product is available in Denmark. The first shipment has arrived, and sales of the product can begin. 18-11-2022Communiqué from extraordinary general meeting in STENOCARE A/S 15-11-2022STENOCARE A/S (“Stenocare”) announces additional financing and imminent scale up of sales 28-10-2022Stenocare accesses the Norwegian market. Stenocare has signed a distribution agreement with the leading distributor and pharmacy chain. 27-10-2022Notice to Extraordinary General Meeting in STENOCARE A/S 14-10-2022STENOCARE approved to supply Danish patients with new CBD medical cannabis oil product 20-09-2022Breakthrough results from new medical cannabis oil study 24-08-2022STENOCARE enters its 4[th] market starting sales in Australia in Q4 2022 19-05-2022COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE 16-05-2022STENOCARE delivers first product batch to the Danish market 04-05-2022Notice to Annual General Meeting in STENOCARE A/S 02-05-2022STENOCARE is ready to start delivery of their THC oil products to Danish patients 10-03-2022STENOCARE initiates guidance: 15-20mDKK in annual revenue run rate by end of 2022 25-02-2022STENOCARE enters the UK market with three medical cannabis oil products 17-01-2022STENOCARE announces positive outcome of feasibility study 07-01-2022STENOCARE is the only supplier of medical cannabis oil under the Danish Pilot Programme 07-01-2022STENOCARE approved to supply Danish patients with medical cannabis oil products 02-12-2021STENOCARE comments on today’s legalization of medical cannabis in Denmark 30-11-2021STENOCARE sign supply agreement with AgMedica Bioscience Inc 29-11-2021STENOCARE supplier update 29-11-2021STENOCARE comments on the business perspective of its Danish indoor cultivation facility 10-09-2021STENOCARE’s world-class cultivation facility is completed 25-05-2021Good news for the Danish medical cannabis patients and for the industry 20-05-2021COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE 05-05-2021Notice to Annual General Meeting in STENOCARE A/S 12-02-2021New medical cannabis oil product for Swedish patients 23-12-2020First delivery to Swedish patients with medical cannabis oil 03-12-2020Good News: U.N. Reclassifies Cannabis as a Less Dangerous Drug 08-09-2020STENOCARE and Emerald have been accepted by Swedish health authorities to offer patients’ treatment with medical cannabis oil 12-08-2020STENOCARE shares traded on the Börse Berlin 30-06-2020STENOCARE is debt free 17-06-2020STENOCARE – Rights issue registered and warrants exercised 15-06-2020STENOCARE rights issue received subscriptions of DKK 117 million or 392% 09-06-2020STENOCARE: Status from Founders’ transactions to satisfy demand for subscription rights 09-06-2020STENOCARE founders to satisfy demand for subscription rights 27-05-2020STENOCARE – Today is the first day of subscribing for the share issue 18-05-2020STENOCARE – Today is the first day of trading on Nasdaq First North Growth Market Denmark 14-05-2020COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE 13-05-2020STENOCARE – First day of trading on NASDAQ FIRST NORTH GROWTH MARKET DENMARK will be 18 May 2020 11-05-2020STENOCARE founders to offer a free share for subscribers 11-05-2020RAISING UP TO 45 MILLION DKK FOR INTERNATIONAL ACCELERATION 11-05-2020DECISION TO LIST AND PUBLICATION OF PROSPECTUS 29-04-2020Notice to Annual General Meeting in STENOCARE A/S 16-03-2020Communiqué from extraordinary general meeting in STENOCARE A/S 11-03-2020STENOCARE signs agreement with new prominent supplier, PANAXIA and announces imminent product approval application filing 28-02-2020Notice to Extraordinary General Meeting in STENOCARE A/S 27-02-2020STENOCARE: New video regarding the profitable Year-End Report 2019 and the road ahead 14-01-2020STENOCARE: Notification of changes in major shareholding and increased holding of own shares. 13-01-2020STENOCARE enters final settlement agreement with CannTrust 19-12-2019STENOCARE sign strategic development partnership with Solural Pharma 13-11-2019STENOCARE and OWC Pharmaceutical Research Corp. to enter partnership to develop advanced medical cannabis products 07-11-2019STENOCARE sign supply agreement with Emerald Health Therapeutics Inc 31-10-2019STENOCARE CEO looks ahead after the first year as a listed company 30-09-2019STENOCARE successfully completes its first harvest without use of pesticides 19-09-2019STENOCARE terminates license agreement with CannTrust and prepares for new partnerships 05-09-2019Change in Board of Directors 20-08-2019Additional cultivation related issues identified at CannTrust 16-07-2019STENOCARE to establish the world’s first hybrid, in-door cultivation facility for production of premium medical cannabis at scale 11-07-2019STENOCARE receives new information from CannTrust that causes immediate quarantine on sales of products from current inventory 09-07-2019STENOCARE UNHARMED BY HEALTH CANADA’S AUDIT OF CANNTRUST 01-07-2019STENOCARE enters the Irish market with its own subsidiary 25-06-2019Danish cannabis cultivation commenced 24-05-2019STENOCARE A/S is ready with new medical cannabis product 23-05-2019STENOCARE A/S has been declared IPO of the Year 2018 16-05-2019Communique from the Annual General Meeting of STENOCARE A/S 01-05-2019Notice to Annual General Meeting in STENOCARE A/S 05-04-2019Shareholders in STENOCARE A/S nominate new member to the Board of Directors 29-03-2019Danish cannabis production due to start shortly 20-03-2019STENOCARE products are being used in clinical trials at Rigshospitalet Multiple Sclerosis Center 10-12-2018STENOCARE A/S on track with the planned offering of Medical Cannabis Capsules to offer Danish patients more choice in their treatment 30-11-2018STENOCARE A/S experiences positive demand and imports the second batch of medical cannabis oil products 29-10-2018Gemstone Capital ApS has decided to exercise 45,000 warrants 26-10-2018First day of trading in STENOCARE A/S shares on Spotlight Stock Market 12-10-2018STENOCARE A/S new share issue significantly oversubscribed 24-09-2018The subscription period in STENOCARE A/S’s new share issue begins today 21-09-2018STENOCARE A/S – the first medical cannabis IPO in Europe – has been approved for listing on Spotlight Stock Market
